Positron Emission Tomography (PET) Imaging of Paediatric Patients with High-Risk Neuroblastoma Using 64Cu-SARTATE: A Multi-Centre, Open-Label, Non-Randomised, Phase-1 Imaging Investigation.

Clarity Pharmaceuticals LTD0 个研究点目标入组 10 人开始时间: 2017年8月30日最近更新: 2018年12月10日

试验速览

暂无简介。

•1. Signed informed consent by parent or guardian.
•2. Age at diagnosis less than or equal to 16 years.
•3. Life expectancy greater than or equal to 12 weeks.
•4. High-risk neuroblastoma with failure to respond to standard therapy, or development of progressive disease at any time, or patients with unresectable residual primary tumours if unsuitable for external beam radiotherapy.
•5. At least one site of disease evaluable by 123I-MIBG SPECT.
•6. Adequate recovery from acute toxic effects of any prior therapy.
•7. At least one site of somatostatin receptor 2 positive malignancy.
•8. Adequate renal function.
•9. Karnofsky or Lansky performance status of greater than or equal to 50.

•1. Patients with disease of any major organ system that would compromise their ability to tolerate therapy, as deemed by the principal investigator or treating sub-investigator.
•2. Patients who require sedation during imaging procedures.
•3. Patients must not receive chemotherapy, anti-cancer cytokine therapy or
•other investigational agents within 2 weeks prior to Day 1.
•4. Patients must not be undergoing treatment with long acting somatostatin analogues (administered within 28 days prior to Day 1), or short acting somatostatin analogues (administered within 24hrs prior to Day 1).
•5. Patients who are pregnant or lactating are excluded. Patients of childbearing potential must practice an effective method of birth control.
•6. Patients who are on hemodialysis.
•7. Patients with a QTc interval less than or equal to 0.45 seconds as measured by screening ECG.
•8. Patients with uncontrolled infections.
•9. Any serious medical condition which the investigator feels may interfere with the
•procedures or evaluations of the study.

发起方